<DOC>
	<DOC>NCT01843946</DOC>
	<brief_summary>Roxithromycin is effective in the treatment of intracellular organisms, including chlamydia and mycoplasma, and exhibits anti-inflammatory and immunomodulatory effects on respiratory diseases. To explore the potential therapeutic benefit of roxithromycin in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), this study compared the effect of roxithromycin with ciprofloxacin and aceclofenac.</brief_summary>
	<brief_title>Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome</brief_title>
	<detailed_description>A total of 75 patients with CP/CPPS were randomized to three groups in open-label: group 1, ciprofloxacin; group 2, aceclofenac; and group 3, roxithromycin. The patients were treated for 4 weeks and were subsequently followed for 12 weeks. Changes from baseline in the total and domain scores of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) were evaluated.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Prostatitis</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Diagnosis of category IIIa of IIIb chronic prostatitis NIHCPSI (National Institute of Health Chronic Prostatitis Symptom Index) score â‰¥ 15 Urinary tract infection or uropathogen within the past 12 months Serious medical problems NIH consensus exclusion criteria13 (presence of active urethritis, urogenital cancer, urinary tract disease, functionally significant urethral stricture, neurological disease affecting the bladder, etc.) Drug therapy that might affect lower urinary tract functions within the past 3 months</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>